SCHEMBL6901805

SCHEMBL6901805

C=C(C)COc1ccc2c(C)cc(=O)oc2c1C(=O)C=Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.60
ALDH1A1 P00352 7/20 0.57
GAA P10253 3/20 0.57
MAPT P10636 9/20 0.54
LMNA P02545 5/20 0.54
HTT P42858 3/20 0.54
SRC P12931 1/20 0.54
PLIN1 O60240 1/20 0.54
RAB9A P51151 1/20 0.54
PLIN5 Q00G26 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ABHD5 Q8WTS1 1/20 0.54
HPGD P15428 4/20 0.53
KMT2A Q03164 3/20 0.52
POLB P06746 1/20 0.52
MAOA P21397 1/20 0.49
FHIT P49789 1/20 0.48
PAX8 Q06710 1/20 0.48
NPC1 O15118 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6905179 0.89 MAPT (0.56) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL6899190 0.89 KDM4E (0.52) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL6898972 0.89 KDM4E (0.57) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL6903392 0.87 MAPT (0.56) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL6903339 0.87 MAPT (0.60) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL6905188 0.85 MAPT (0.54) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL7072943 0.82 ALDH1A1 (0.41) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL7172080 0.78 MAPT (0.50) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL6901231 0.78 MAPT (0.56) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL6903967 0.77 MAPT (0.51) KDM4EALDH1A1GAAMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1212311-B1 CHALCONE COUMARINS INDENA SPA (IT) 2003-03-26 EP claimed
US-20020161036-A1 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment INDENA S.P.A. (IT) 2002-10-31 US claimed
EP-1212311-A1 CHALCONE COUMARINS INDENA S.p.A. (IT) 2002-06-12 EP claimed
WO-2001017984-A1 CHALCONE COUMARINS INDENA S.P.A. (IT) 2001-03-15 WO claimed
US-6767916-B2 1-(4-METHYL-7-(3-METHYLBUT-2-ENYLOXY)COUMARIN-8-YL)-3-(PYRIDIN E-3-YL)- PROPEN-1-ONE FOR EXAMPLE; ANTIPROLIFERATIVE AGENT; TUMOR, CANCER TREATMENT INDENA S.P.A. (IT) 2004-07-27 US disclosed
EP-1212311-B1 CHALCONE COUMARINS INDENA SPA (IT) 2003-03-26 EP disclosed
US-20020161036-A1 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment INDENA S.P.A. (IT) 2002-10-31 US disclosed
EP-1212311-A1 CHALCONE COUMARINS INDENA S.p.A. (IT) 2002-06-12 EP disclosed
WO-2001017984-A1 CHALCONE COUMARINS INDENA S.P.A. (IT) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161036-A1 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment NFKBIA, MKI67, HPD KDM4E 201/4885ALDH1A1 1741/4885GAA 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.